The ConcertAI Podcast – Détails, épisodes et analyse

September marks Prostate Cancer Awareness Month, and to honor this, our latest episode of the ConcertAI Podcast features a special session with top urological cancer specialists. Host Jeff Elton welcomes Jennifer Rider and Kathryn Penney to our studio in Harvard Square, Cambridge, MA. Both guests are distinguished cancer epidemiologists who bring a wealth of knowledge and experience in prostate cancer research. 

In this episode, you will hear about the personal journeys of our guests into the field of cancer research, the significant advancements they have contributed to, and the vital role of genetic studies in improving patient care. The discussion delves into the importance of the Gleason scoring system for determining patient prognosis and explores the integration of AI and digital pathology to enhance diagnosis and treatment strategies. This conversation is essential for anyone interested in the latest in prostate cancer research and the evolving treatment strategies that could redefine patient outcomes.

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

Jeff Elton sits down with Dr. Robert Miller, Chief Medical and Science Officer at CancerLinQ, to unpack the integration of real-world data and AI in oncology care. Dr. Miller shares his journey from community practice to shaping CancerLinQ, revealing insights into the network's growth and its pivotal role in improving patient care. The episode delves into the transformation of quality measures, the burgeoning role of electronic health records, and the automation of data to enhance the quality and reach of oncological care. As CancerLinQ evolves, discover its expanding capabilities, the drive towards patient-centric care, and the influence on CancerLinQ's partnerships, particularly with ASCO. This is a must-listen for professionals seeking to understand the landscape of data-driven healthcare improvements. Tune in to explore the trajectory of oncology practice transformation with two industry leaders at the helm.

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

In this episode of the ConcertAI podcast, join our CEO Jeff Elton and Dan McSweeney, President of TeraRecon, ConcertAI's digital imaging solution, for an informative and engaging discussion. TeraRecon is a leading solution for three-dimensional radiological interpretation, but what makes them stand out is their novel approach of integrating AI directly into care delivery models.

 Jeff and Dan explore the unique position of TeraRecon in the healthcare workflow and how their neutrality sets them apart from other players in the space. They also discuss the potential of AI in radiology and how it can reduce variation in clinical outcomes while increasing productivity.

Don't miss out on this exciting exchange about healthcare technology and innovation. Tune in now to join the conversation!

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

Don't miss out on the latest episode of The ConcertAI Podcast featuring Catherine Richards, ConcertAI's chief data officer! Join us as we dive into the state of the field of real world data, why it's transforming, and how research is now enabled because of it. Tune in to gain more understanding about data sets and analyses derived from real world data. Click the link to listen now! 

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

On this episode of The ConcertAI Podcast, we're  joined by SVP of Clinical Development Technologies, Luke Dunlap. Luke and Jeff discuss the experience and  transformation about how clinical trials are being conducted with some of the newest technologies and the value that's being realized. Take a deeper dive into our end-to-end software platform, Digital Trial Solutions, is being used to conduct pharmaceutical studies at clinical research sites and how it is subsequently reducing patient burden. You'll also hear about ConcertAI's Clinical Trial Optimization software system and how it is improving the efficiency of clinical research protocols. Learn how we are transforming and accelerating biomedical innovations over the course of the next two to five years. 

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

On this episode we are joined by Dr. Warren Whyte. Dr. Whyte heads up ConcertAI’s health equity and trial diversity initiatives through the ERACE (Engaging Research to Achieve Cancer Care Equity) program . As a leader in this field, his work and the work of his team has influenced all of what ConcertAI brings to clients, customers, and biopharma partners. This includes the integration of SDOH with all of our datasets - a first-in-class for anybody in the RWD Industry. His work also influenced integrating health equity and trial diversity considerations into all of our technology solutions. There couldn't be a more important topic with a more influential individual in the field!

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

On our first episode, special guest Claudio D'Ambrosio covers the topic of multi-modal data in biomedical research. Multi-modal data can allow some of the deepest most advanced research questions to be answered. We start with the questions and then we bring together layers of different data, of different origin, that surround the patient in service of that particular question. This will change and transform how we develop and test hypothesis and will accelerate early phase trial activities. 

D'Ambrosio also touches on ConcertAI's value of partnering. Biomedical innovations is a team sport. It requires the inputs of multiple types of expertise. It’s in the dynamics operating as a single company or single entity that we can really transform the performance of research activities.

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

The ConcertAI Podcast is a monthly podcast which brings together subject matter experts who take a deeper dive on topics of interest and relevance like real world data, real world evidence, clinical development technologies and patient facing solutions for clinical diagnosis.

To learn more please visit us at www.ConcertAI.com

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

Jeff Elton, CEO of ConcertAI, and George Sledge, CMO of Caris Life Sciences, embark on an insightful journey through the advancements in oncology. They explore the transformative power of molecular diagnostic testing and how comprehensive data sets are revolutionizing personalized medicine. Delving into topics like the rise of liquid biopsies, which enable non-invasive, next-gen sequencing, they highlight the potential for easier and safer tumor monitoring. Challenges like the limitations of analyzing small populations are addressed, emphasizing the value of large-scale, actionable databases in understanding diseases like breast cancer. They also discuss the future of molecular diagnostics in streamlining cancer prevention trials and the need to look beyond "gateway mutations" for a deeper understanding of dynamic cancer evolution. A key theme is the collaborative synergy between ConcertAI and Caris Life Sciences, emphasizing the goal of producing high-quality, meaningful data that can shape the future of oncological research and care.

Interested in learning more about ConcertAI and Caris Life Science's joint offering? Download our factsheet today!

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai